Antiangiogenesis for cancer therapy

Lancet

Volumn 349, Issue SUPPL.2, 1997, Pages

  Harris, Adrian L ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTIBODY; ANTINEOPLASTIC AGENT; BACTERIAL TOXIN; FUMAGILLOL CHLOROACETYLCARBAMATE; INTERFERON; METALLOPROTEINASE INHIBITOR; VASCULOTROPIN;

ANGIOGENESIS; CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; HUMAN; PRIORITY JOURNAL; SHORT SURVEY; TUMOR VASCULARIZATION;

EID: 0030982113     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0140-6736(97)90014-3     Document Type: Article

References (19)

1. Weidner N, Folkman J, Pozza F, et al. Tumour angiogenesis: a new significant and independent prognostic indictor in early-stage breast carcinoma. J Natl Cancer Inst 1992; 84: 1875-87.
2. Horak ER, Leek R, Klenk N, et al. Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastasis and survival in breast cancer. Lancet 1992; 340: 1120-24.
3. Folkman J. What is the evidence that tumours are angiogenesis dependent? J Natl Cancer Inst 1990; 82: 4-6.
4. Contrino J, Hair G, Kreutzer DL, Rickles FR. In-situ detection of tissue factor in vascular endothelial-cells - correlation with the malignant phenotype of human breast disease. Nat Med 1996; 2: 209-15.
5. Brooks PC. Cell-adhesion molecules in angiogenesis. Cancer Metastasis Rev 1996; 15: 187-94.
6. Claffey KP, Robinson GS. Regulation of VEGF/VPF expression in tumor-cells - consequences for tumor-growth and metastasis. Cancer Metastasis Rev 1996; 15: 165-76.
7. O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin - a novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung-carcinoma. Cell 1994; 79: 315-28.
8. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-64.
9. Graeber TG, Osmanian C, Jacks T, et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors. Nature 1996; 379: 88-91.
10. Mukhopadhyay D, Tsiokas L, Sukhatme VP. Wild-type p53 and v-src exert opposing influences on human vascular endothelial growth-factor gene-expression. Cancer Res 1995; 55: 6161-65.
11. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases - balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1995; 1: 149-53.
12. Bunn HF, Poyton RO. Oxygen sensing and molecular adaptation to hypoxia. Physiol Rev 1996; 76: 839-85.
13. Iliopoulos O, Levy AP, Jiang C, Kaelin WG, Goldberg MA. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci USA 1996; 93: 10595-99.
14. Teicher BA. Angiogenesis and cancer metastases - therapeutic approaches. Crit Rev Oncol Hematol 1995; 20: 9-39.
15. Brown PD, Giavazzi R. Matrix metalloproteinase inhibition - a review of antitumor-activity. Ann Oncol 1995; 6: 967-74.
16. Min HY, Doyle LV, Vitt CR, et al. Urokinase receptor antagonists inhibit angiogenesis and primary tumor-growth in syngeneic mice. Cancer Res 1996; 56: 2428-33.
17. Millauer B, Longhi MP, Plate KH, et al. Dominant-negative inhibition of flk-1 suppresses the growth of many tumor types in-vivo. Cancer Res 1996; 56: 1615-20.
18. Wilson WR, Pruijn FB. Hypoxia-activated prodrugs as antitumor agents - strategies for maximizing tumor-cell killing. Clin Exp Pharmacol Physiol 1995; 22: 881-85.
19. Parangi S, O'Reilly M, Christofori G, et al. Antiangiogenic therapy of transgenic mice impairs de-novo tumor-growth. Proc Natl Acad Sci USA 1996; 93: 2002-07.